Cambridge Investment Research Advisors, Inc. Esperion Therapeutics, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

  • $29.4 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 04, 2021
SELL
$24.2 - $35.76 $236,434 - $349,375
-9,770 Closed
0 $0
Q3 2020

Oct 29, 2020
BUY
$31.18 - $52.71 $167,904 - $283,843
5,385 Added 122.81%
9,770 $363,000
Q2 2020

Jul 27, 2020
BUY
$30.04 - $51.31 $131,725 - $224,994
4,385 New
4,385 $224,000
Q1 2020

May 08, 2020
SELL
$27.44 - $73.84 $92,363 - $248,545
-3,366 Closed
0 $0
Q4 2019

Feb 04, 2020
BUY
$35.4 - $59.82 $119,156 - $201,354
3,366 New
3,366 $200,000

Others Institutions Holding ESPR

# of Institutions
206
Shares Held
128M
Call Options Held
1.67M
Put Options Held
930K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $153M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email